Document Detail


Ventricular fibrillation following administration of thrombolytic treatment. The EMIP experience. European Myocardial Infarction Project.
MedLine Citation:
PMID:  8732374     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Reperfusion-induced ventricular fibrillation has been demonstrated in animal models of myocardial ischaemia, but no evidence exists for this in humans. The European Myocardial Infarction Project compared the efficacy and safety of pre-hospital thrombolytic therapy with that of hospital therapy. The objective of this study was to investigate the occurrence of reperfusion-induced ventricular fibrillation in acute myocardial infarction patients following thrombolytic therapy. In a double-blind multicentre trial, eligible patients were randomized to receive anistreplase at home followed by placebo in the hospital (A/P group), or placebo followed by anistreplase (P/A group). The occurrence of ventricular fibrillation, and other adverse events were recorded on specific study forms and could be attributed to defined time intervals. The incidence of ventricular fibrillation in the A/P group was significantly higher following the pre-hospital injection than in the P/A group (2.5% vs 1.6%; P = 0.021); the situation was reversed following the hospital injection (3.6% vs 5.3%; P = 0.002). No relationship was found between this excess of ventricular fibrillation and the patients' condition, with the exception of the site of the infarct. These results suggest the existence of reperfusion-induced ventricular fibrillation in patients developing myocardial infarction who receive thrombolytic treatment.
Authors:
J P Boissel; A Castaigne; C Mercier; L Lion; A Leizorovicz
Related Documents :
10580214 - A community hospital's effort to expedite treatment for patients with chest pain.
8430624 - Myocardial infarct artery patency and reocclusion rates after treatment with duteplase ...
2188764 - Future directions in plasminogen activator therapy.
10639264 - Invasive strategies to achieve infarct-related artery patency.
3566984 - Sarcoidosis: a pattern of clinical and morphological presentation.
15771924 - New cut-off values of cardiac markers for risk stratification of angina pectoris.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  17     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-09-24     Completed Date:  1996-09-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  213-21     Citation Subset:  IM    
Affiliation:
Service de Pharmacologie Clinique, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase / therapeutic use*
Double-Blind Method
Fibrinolytic Agents / therapeutic use*
Hospital Mortality
Humans
Myocardial Infarction / complications,  drug therapy*
Myocardial Reperfusion / adverse effects*
Survival Rate
Thrombolytic Therapy / adverse effects*
Ventricular Fibrillation / etiology*,  mortality
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase
Comments/Corrections
Comment In:
Eur Heart J. 1996 Feb;17(2):172-3   [PMID:  8732368 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determinants of exercise capacity in patients with coronary artery disease and mild to moderate syst...
Next Document:  Dobutamine stress echocardiography after coronary artery bypass grafting. Transthoracic vs biplane t...